[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL146934A0 - Use of antibodies afainst cd20 for the treatment of the graft versus host disease - Google Patents

Use of antibodies afainst cd20 for the treatment of the graft versus host disease

Info

Publication number
IL146934A0
IL146934A0 IL14693400A IL14693400A IL146934A0 IL 146934 A0 IL146934 A0 IL 146934A0 IL 14693400 A IL14693400 A IL 14693400A IL 14693400 A IL14693400 A IL 14693400A IL 146934 A0 IL146934 A0 IL 146934A0
Authority
IL
Israel
Prior art keywords
afainst
antibodies
treatment
host disease
versus host
Prior art date
Application number
IL14693400A
Other languages
English (en)
Original Assignee
Consiglio Naz Delle Richerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Naz Delle Richerche filed Critical Consiglio Naz Delle Richerche
Publication of IL146934A0 publication Critical patent/IL146934A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL14693400A 1999-06-11 2000-06-07 Use of antibodies afainst cd20 for the treatment of the graft versus host disease IL146934A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
IL146934A0 true IL146934A0 (en) 2002-08-14

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14693400A IL146934A0 (en) 1999-06-11 2000-06-07 Use of antibodies afainst cd20 for the treatment of the graft versus host disease

Country Status (26)

Country Link
US (1) US20070014785A1 (xx)
EP (1) EP1185299B1 (xx)
JP (1) JP2003501482A (xx)
KR (1) KR20020026455A (xx)
CN (1) CN1253208C (xx)
AU (1) AU774206B2 (xx)
BG (1) BG106193A (xx)
CA (1) CA2376288A1 (xx)
CZ (1) CZ20014450A3 (xx)
DE (1) DE60033030T2 (xx)
DK (1) DK1185299T3 (xx)
EE (1) EE200100667A (xx)
ES (1) ES2278616T3 (xx)
HK (1) HK1043549B (xx)
HU (1) HUP0201600A3 (xx)
IL (1) IL146934A0 (xx)
IS (1) IS6195A (xx)
IT (1) ITMI991299A1 (xx)
NO (1) NO20016035L (xx)
NZ (1) NZ515992A (xx)
PL (1) PL352860A1 (xx)
PT (1) PT1185299E (xx)
SK (1) SK18132001A3 (xx)
TR (1) TR200103581T2 (xx)
WO (1) WO2000076542A1 (xx)
ZA (1) ZA200110004B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
SG2013036975A (en) * 2002-12-16 2016-07-28 Genentech Inc Immunoglobulin variants and uses thereof
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
UA91961C2 (ru) 2003-04-09 2010-09-27 Дженентек, Инк. Лечение аутоимунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
EP2960251A1 (en) 2003-05-09 2015-12-30 Duke University CD20-specific antibodies and methods of employing same
WO2005000351A2 (en) 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
EP1730288B1 (en) * 2004-03-22 2013-05-15 The Ohio State University Research Foundation Methods for transfecting natural killer cells
EP3130349A1 (en) 2004-06-04 2017-02-15 Genentech, Inc. Method for treating multiple sclerosis
EP2213683B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant Fc regions
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
KR101251157B1 (ko) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37-특이적 결합 분자 및 ｃｄ20-특이적 결합 분자를사용한 ｂ-세포 감소
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
JP5403752B2 (ja) 2007-06-22 2014-01-29 北海道公立大学法人 札幌医科大学 移植片対宿主疾患の検査および治療方法
JP5687057B2 (ja) 2007-07-09 2015-03-18 ジェネンテック， インコーポレイテッド ポリペプチドの組換え生産中におけるジスルフィド結合還元の防止
NZ583019A (en) 2007-07-31 2011-05-27 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
CA2701329C (en) 2007-10-16 2017-08-22 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
SG178358A1 (en) 2009-08-11 2012-03-29 Genentech Inc Production of proteins in glutamine-free cell culture media
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
MY180297A (en) 2015-06-24 2020-11-27 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
IL280875B1 (en) 2018-08-31 2024-08-01 Regeneron Pharma Cytokine Release Syndrome Attenuating Dosing Strategy for Bispecific Antibodies to CD3 and CD20
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ333053A (en) * 1996-05-31 2000-06-23 Genetic Therapy Inc Use of an interaction agent or T-cells having polynucleotides encoding negative selective markers to prevent graft-versus-host disease
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
ZA200110004B (en) 2003-02-26
ITMI991299A0 (it) 1999-06-11
HUP0201600A3 (en) 2005-04-28
CA2376288A1 (en) 2000-12-21
EE200100667A (et) 2003-02-17
HUP0201600A2 (en) 2002-08-28
SK18132001A3 (sk) 2002-05-09
AU774206B2 (en) 2004-06-17
HK1043549A1 (en) 2002-09-20
DK1185299T3 (da) 2007-05-21
WO2000076542A1 (en) 2000-12-21
ES2278616T3 (es) 2007-08-16
CZ20014450A3 (cs) 2002-04-17
CN1253208C (zh) 2006-04-26
AU5530300A (en) 2001-01-02
EP1185299A1 (en) 2002-03-13
KR20020026455A (ko) 2002-04-10
DE60033030T2 (de) 2007-05-31
TR200103581T2 (tr) 2002-08-21
IS6195A (is) 2001-12-10
DE60033030D1 (de) 2007-03-08
EP1185299B1 (en) 2007-01-17
CN1355712A (zh) 2002-06-26
PL352860A1 (en) 2003-09-08
PT1185299E (pt) 2007-03-30
ITMI991299A1 (it) 2000-12-11
NO20016035D0 (no) 2001-12-10
HK1043549B (zh) 2006-09-01
BG106193A (bg) 2002-08-30
JP2003501482A (ja) 2003-01-14
NZ515992A (en) 2004-01-30
NO20016035L (no) 2002-02-11
US20070014785A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
IL146934A0 (en) Use of antibodies afainst cd20 for the treatment of the graft versus host disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AUPQ302899A0 (en) Implants for the use in the treatment of aneurysmal disease
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
IL160998A0 (en) Human tissue factor antibodies
HUP0400775A2 (en) Specific human antibodies for selective cancer therapy
AU8322401A (en) Indole compounds useful for the treatment of cancer
MXPA02004942A (es) Nuevo uso de anticuerpos como vacunas.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
SI1185299T1 (sl) Uporaba protiteles proti cd20 za zdravljenje reakcije presadka proti gostitelju
HRP20020262A2 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU6896300A (en) Vaccines for the treatment of autoimmune disease
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB9914057D0 (en) Antibody therapy
IL131335A0 (en) Emulsions for cancer treatment
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
TJ360B (en) Collection mizoj for the treating of drug addiction
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies